How to Start a Ketamine Therapy Practice: A Clinician's Guide

Introduction

The rapid expansion of clinical evidence supporting low-dose ketamine for treatment-resistant depression (TRD), chronic pain, and other psychiatric conditions has generated significant interest among clinicians seeking to incorporate ketamine therapy into their practice. However, launching a ketamine therapy service involves navigating a complex intersection of federal drug scheduling requirements, state medical regulations, clinical protocol development, and business considerations that extend well beyond standard prescribing.

This guide provides a structured framework for clinicians -- psychiatrists, anesthesiologists, pain medicine specialists, emergency physicians, and other qualified prescribers -- who are evaluating the feasibility of starting a ketamine therapy practice. The information presented here reflects the regulatory landscape and clinical standards current as of early 2026, though clinicians should verify state-specific requirements as this field continues to evolve.

Federal and State Licensing Requirements

DEA Registration

Ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act. Any clinician who intends to prescribe, administer, or dispense ketamine must hold a valid Drug Enforcement Administration (DEA) registration. Most physicians, nurse practitioners, and physician assistants who already prescribe controlled substances will have an active DEA registration. However, clinicians should verify that their registration covers Schedule III substances and that the registered address corresponds to the practice location where ketamine will be administered or prescribed.

For clinicians establishing a new practice location, a separate DEA registration may be required for each principal place of business. The application process (DEA Form 224 for new registrations) typically takes four to six weeks, and clinicians should initiate this well in advance of their intended launch date.

State Medical Board Regulations

State-level regulation of ketamine therapy varies considerably. Some states have enacted specific statutes governing the administration of ketamine for psychiatric indications, while others rely on general medical practice acts and off-label prescribing authority. Key regulatory considerations include:

• Scope of practice: Whether non-physician prescribers (NPs, PAs) can independently prescribe or administer ketamine, or whether physician supervision is required
• Practice setting requirements: Some states mandate that IV ketamine be administered in clinical settings equipped for emergency resuscitation; oral and sublingual formulations may have different requirements
• Telemedicine prescribing: Regulations governing remote prescribing of ketamine have tightened following the expiration of pandemic-era flexibilities -- clinicians must verify whether their state permits telehealth-based ketamine prescribing and under what conditions
• Reporting obligations: Prescription drug monitoring program (PDMP) reporting requirements apply to ketamine prescriptions in most states

Clinicians should consult their state medical board, state pharmacy board, and a healthcare attorney familiar with controlled substance regulations before initiating practice.

Facility Requirements

The physical infrastructure required depends on the route of administration. IV infusion practices require clinical space equipped with cardiac monitoring, pulse oximetry, suction equipment, supplemental oxygen, and emergency medications including benzodiazepines for acute agitation and vasodilators for hypertensive emergencies. Practices offering oral or sublingual ketamine with in-office monitoring require similar -- though potentially less intensive -- monitoring capabilities.

Clinicians should ensure their facility meets applicable state health department licensing requirements, occupational safety standards, and Americans with Disabilities Act (ADA) accessibility requirements.

Developing Clinical Protocols

Patient Selection and Screening

Rigorous patient selection criteria form the cornerstone of safe ketamine practice. A standardized intake protocol should include:

• Psychiatric evaluation: Comprehensive diagnostic assessment confirming the target condition, treatment history documenting adequate trials of first-line therapies, and screening for psychotic spectrum disorders and active substance use disorders
• Medical evaluation: Focused history addressing cardiovascular risk factors, hepatic and renal function, pregnancy status, and current medication review with specific attention to drug interactions
• Baseline assessments: Validated symptom rating scales (PHQ-9, MADRS, or equivalent), vital signs, and baseline cognitive screening where appropriate
• Contraindication screening: Systematic evaluation for uncontrolled hypertension, active psychosis, elevated intracranial pressure, unstable aneurysmal vascular disease, and other contraindications

Informed Consent

Given that most ketamine therapy for psychiatric indications represents off-label use, the informed consent process carries particular importance. A legally and ethically sound consent document should address:

• The off-label nature of the treatment and the distinction from FDA-approved esketamine (Spravato)
• Expected benefits, response rates, and the evidence base supporting treatment
• Known risks and side effects, including dissociative experiences, cardiovascular effects, nausea, and the potential for psychological dependence
• The experimental or evolving nature of long-term maintenance protocols
• Alternative treatment options
• Financial obligations, including the likelihood that treatment will not be covered by insurance

Treatment Protocols

Clinicians should develop written treatment protocols specifying:

• Dosing parameters: Initial doses, titration schedules, and maximum doses for each route of administration -- sub-anesthetic dose ranges and weight-based dosing guidelines provide frameworks
• Monitoring requirements: Vital sign frequency, dissociation assessment intervals, and criteria for dose adjustment or treatment discontinuation
• Session procedures: Pre-treatment checklist, administration procedures, observation period duration, and discharge criteria (including cognitive assessment and confirmation of safe transportation)
• Emergency protocols: Step-by-step procedures for managing hypertensive crisis, laryngospasm, severe dissociation, emergence phenomena, and anaphylaxis

Outcome Tracking

Systematic outcome measurement using validated instruments is essential for clinical decision-making and practice quality assurance. Clinicians should establish protocols for administering standardized assessments at defined intervals -- typically before each treatment session during the induction phase and at regular intervals during maintenance. The PHQ-9, MADRS, and other clinical scales provide structured frameworks for tracking treatment response.

Compounding Pharmacy Partnerships

Selecting a Compounding Pharmacy

Clinicians prescribing oral, sublingual, or intranasal ketamine formulations will typically work with compounding pharmacies, as commercially manufactured products in these formulations are limited. When evaluating compounding pharmacy partners, clinicians should verify:

• Accreditation: Pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or holding applicable state compounding licenses demonstrate commitment to quality standards
• 503A vs. 503B status: Section 503A pharmacies compound pursuant to individual patient prescriptions; Section 503B outsourcing facilities can produce larger batches without patient-specific prescriptions and are subject to FDA Current Good Manufacturing Practice (cGMP) requirements
• Testing and quality assurance: Potency testing, sterility testing (for injectable preparations), beyond-use dating studies, and certificate of analysis documentation
• Formulation expertise: Experience with ketamine-specific formulations, including sublingual troches, rapid-dissolve tablets, and nasal spray preparations with appropriate concentrations and flavoring

Formulation Considerations

Common compounded ketamine formulations include:

• Sublingual troches/lozenges: Typically prepared in doses ranging from 50 mg to 300 mg, designed for buccal absorption with higher bioavailability than swallowed oral preparations
• Rapid-dissolve tablets (RDTs): Sublingual formulations designed for faster dissolution
• Nasal spray: Compounded racemic ketamine nasal spray (distinct from FDA-approved esketamine) in concentrations typically ranging from 50-100 mg/mL
• Oral solutions: Liquid preparations allowing flexible dosing

Clinicians should maintain documentation of their compounding pharmacy's quality assurance processes and be prepared to demonstrate due diligence in pharmacy selection if questions arise during malpractice review or regulatory inquiry.

Liability and Risk Management

Malpractice Insurance

Before initiating ketamine therapy, clinicians must confirm that their professional liability insurance covers the administration of ketamine for the intended indications. Key considerations include:

• Off-label coverage: Many standard malpractice policies cover off-label prescribing, but some exclude specific procedures or medications -- written confirmation from the insurer is essential
• Route-specific coverage: IV administration may be classified differently than oral prescribing, particularly for non-anesthesiologist prescribers
• Telemedicine riders: If prescribing via telehealth, confirm that the policy covers telemedicine encounters and the specific states in which patients are located
• Tail coverage: For clinicians transitioning between employers or insurance carriers, ensure continuity of coverage for prior ketamine-related encounters

Documentation Standards

Thorough clinical documentation serves as the primary defense in malpractice claims. Each patient encounter should document:

• Clinical indication and supporting diagnostic criteria
• Treatment history demonstrating treatment resistance or failure of first-line options
• Informed consent discussion and signed consent form
• Pre-treatment vital signs and screening results
• Dose administered, route, and duration of administration
• Intra-treatment monitoring data (vital signs, dissociation level, adverse effects)
• Post-treatment assessment, discharge criteria met, and follow-up plan
• Response to treatment using standardized outcome measures

Risk Mitigation Strategies

Additional risk management measures include:

• Establishing a peer consultation network or clinical advisory relationship with an experienced ketamine provider
• Maintaining current Basic Life Support (BLS) certification at minimum; Advanced Cardiac Life Support (ACLS) is strongly recommended for clinicians administering IV ketamine
• Developing and regularly rehearsing emergency protocols with all clinical staff
• Conducting periodic chart audits to ensure protocol adherence
• Staying current with emerging safety data through continuing medical education and literature review

Insurance and Reimbursement

Current Insurance Landscape

The majority of low-dose ketamine therapy for psychiatric indications remains uninsured or poorly reimbursed. FDA-approved intranasal esketamine (Spravato) represents an exception, as it carries specific CPT codes and REMS program requirements, with insurance coverage available through prior authorization processes. Off-label racemic ketamine -- whether administered intravenously, orally, or sublingually -- is typically a self-pay service.

Billing Strategies

Clinicians may consider several approaches to reimbursement:

• Self-pay models: Transparent per-session pricing for ketamine administration, with separate billing for psychiatric evaluation and management services that may be insurance-eligible
• E/M code billing: Office visit evaluation and management codes (99213-99215) for the psychiatric assessment component of ketamine visits may be submitted to insurance, even when the ketamine administration itself is self-pay
• Infusion codes: For IV administration, CPT codes for IV infusion (96365-96368) and hydration (96360-96361) may be applicable, though reimbursement for off-label indications varies by payer
• Superbills: Providing patients with superbills containing appropriate diagnosis and procedure codes allows patients to seek out-of-network reimbursement from their insurance carriers

Financial Planning

Practice financial models should account for the costs of controlled substance inventory management, monitoring equipment, clinical staffing for observation periods, compounding pharmacy fees, malpractice insurance premiums, and the administrative overhead of managing a self-pay practice including payment processing and collections.

Staffing and Training

Clinical Team Composition

A ketamine therapy practice typically requires:

• Prescribing clinician: Physician, NP, or PA with appropriate licensing and training
• Monitoring staff: Registered nurses or medical assistants trained in ketamine administration, monitoring protocols, and emergency response
• Administrative support: Scheduling, intake coordination, insurance verification (where applicable), and billing

Training Requirements

While no universally mandated ketamine therapy certification exists, clinicians should pursue training through recognized professional organizations and continuing medical education programs. Training should cover pharmacology, patient selection, protocol development, emergency management, and the ethical considerations of off-label prescribing. Several professional societies offer ketamine-specific training programs and practice guidelines.

All clinical staff -- not just the prescribing clinician -- should be trained in monitoring protocols, recognizing adverse events, and initiating emergency procedures. Regular simulation drills for managing hypertensive emergencies, severe dissociation, and respiratory compromise are recommended.

Building a Referral Network

Successful ketamine practices typically receive referrals from psychiatrists, primary care physicians, pain management specialists, and psychotherapists whose patients have not responded adequately to conventional treatments. Building referral relationships requires:

• Educating referring providers about patient selection criteria, so referrals are appropriate
• Providing clear referral pathways and intake processes
• Communicating treatment outcomes back to referring providers with patient consent
• Establishing collaborative care agreements for patients requiring integrated management of comorbid conditions

Conclusion

Starting a ketamine therapy practice represents both a significant clinical opportunity and a substantial regulatory and operational undertaking. Clinicians who invest in thorough regulatory compliance, evidence-based protocol development, quality compounding partnerships, and robust risk management infrastructure position themselves to provide safe, effective treatment while minimizing legal and professional exposure. As the evidence base for low-dose ketamine continues to mature and regulatory frameworks become more standardized, clinicians who establish well-structured practices now will be positioned to adapt as this rapidly evolving field develops.

References

• DEA Practitioner's Manual: Registration — Comprehensive guide to DEA registration requirements for controlled substance prescribing
• Sanacora G, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405 — Expert consensus on clinical standards for ketamine therapy
• FDA REMS for Spravato (esketamine) — FDA REMS requirements for esketamine, relevant for clinicians offering both racemic and esketamine therapies
• Pharmacy Compounding Accreditation Board (PCAB) — Accreditation standards for compounding pharmacies
• Andrade C. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? J Clin Psychiatry. 2017;78(7):e852-e857 — Clinical dosing parameters for ketamine in psychiatric practice
• Wilkinson ST, et al. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. Am J Psychiatry. 2017;174(7):695-696 — Practice patterns in off-label ketamine prescribing
• National Institute of Mental Health: Ketamine Research — NIMH overview of ketamine research for mental health